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Simple Summary: Consumption of alcohol increases liver damage in HIV people; however, the mech-
anisms remain elusive. By utilizing alcohol (ethanol) exposed HIV-infected human hepatocytes liver
cells and ethanol-fed liver humanized mouse model (immunodeficient mice livers harbor human
hepatocytes), we show that the combination of alcohol and HIV enhances oxidative stress and impairs
lysosome activity, which in turn stimulates pathogenic nanosized extracellular vesicles. These vesicles
are of great importance, as manipulating their numbers and contents will eliminate the spread of
infection in other cell types.
Abstract: Background: Alcohol abuse is common in people living with HIV-1 and dramatically
enhances the severity of HIV-induced liver damage by inducing oxidative stress and lysosomal
dysfunction in the liver cells. We hypothesize that the increased release of extracellular vesicles
(EVs) in hepatocytes and liver humanized mouse model is linked to lysosome dysfunction. Methods:
The study was performed on primary human hepatocytes and human hepatoma RLWXP-GFP (Huh
7.5 cells stably transfected with CYP2E1 and XPack-GFP) cells and validated on ethanol-fed liver-
humanized fumarylacetoacetate hydrolase (Fah)-/-, Rag2-/-, common cytokine receptor gamma chain
knockout (FRG-KO) mice. Cells and mice were infected with HIV-1ADA virus. Results: We observed
an increase in the secretion of EVs associated with a decrease in lysosomal activity and expression
of lysosomal-associated membrane protein 1. Next-generation RNA sequencing of primary human
hepatocytes revealed 63 differentially expressed genes, with 13 downregulated and 50 upregulated
genes in the alcohol–HIV-treated group. Upstream regulator analysis of differentially expressed
genes through Ingenuity Pathway Analysis identified transcriptional regulators affecting downstream
genes associated with increased oxidative stress, lysosomal associated disease, and function and
EVs biogenesis. Our in vitro findings were corroborated by in vivo studies on human hepatocyte-
transplanted humanized mice, indicating that intensive EVs’ generation by human hepatocytes and
their secretion to serum was associated with increased oxidative stress and reduction in lysosomal
activities triggered by HIV infection and ethanol diet. Conclusion: HIV-and-ethanol-metabolism-
induced EVs release is tightly controlled by lysosome status in hepatocytes and participates in the
development of double-insult-induced liver injury.
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1. Introduction
Despite significant improvement in the survival of people living with HIV-1 (PLWH)
in the era of highly efficient antiretroviral therapy, liver disease is emerging as a major cause
of morbidity and mortality [1]. Approximately 48% of PLWH have a history of alcohol
abuse [2]. Alcohol potentiates HIV-mediated liver damage, and alcohol consumption in
PLWH exacerbates liver injury, leading to hepatic fibrosis or cirrhosis. It also enhances
pathological infection features by increasing viremia, suppressing the immune response,
and promoting non-adherence to treatment, resulting in poor HIV treatment outcomes [3,4].
Alcohol also interferes with the biogenesis and lysosomal activity and may contribute to
accumulation or subjected to degradation of proteins (including HIV proteins) in the liver,
which may have harmful hepatotoxic effects [5]. Our group’s previous study demonstrated
that ethanol metabolism potentiates the accumulation of HIV proteins/HIV RNA and
causes oxidative stress and lysosome impairment in the hepatocytes [5].
As demonstrated before, in alcoholic liver disease, human hepatocytes release signifi-
cant amounts of extracellular vesicles (EVs), a typical feature of alcoholic hepatitis [6]. HIV
interaction with multiple hepatic cell types, such as Kupffer cells (KCs) and hepatic stellate
cells (HSCs), has been reported to impair intercellular communication networks for sup-
porting liver homeostasis [7], attributing to an increased EVs release [8]. Endosome-origin
exosomes are excreted from the cells when multivesicular bodies (MVBs) of the endoso-
mal system fuse with the plasma membrane. However, the mechanisms to sort MVBs,
either to the plasma membrane or the lysosome, are unclear. Furthermore, a checking point
between these two fates suggests that one pathway’s inhibition may promote the switch
to another pathway [9,10]. It has also been shown that lysosome inhibition with various
chemicals, such as bafilomycin A1, increases EV secretion [11]. EVs may contain regulatory
molecules, which represent lysosome non-degraded cell products, and this degradation
is suppressed by ethanol (EtOH) metabolism in hepatocytes [5]. The role of EVs in the
context of ethanol and HIV-1 from cells other than hepatocytes is well reported [12,13].
However, the combined effects of HIV and ethanol metabolism on the EVs release and EVs
secretion association with lysosomal activity in hepatocytes have not been examined.
Here, we hypothesize that the combination of HIV infection and ethanol metabolism
causes lysosome dysfunction in hepatocytes, thereby potentiating EVs release from these
cells. Our findings indeed indicate that, in HIV-infected hepatocytes, ethanol metabolites
and, mainly, acetaldehyde (Ach) upregulate the expression of stress-related genes, lead-
ing to lysosome dysfunction and a subsequent increase in EVs secretion from hepatocytes.
2. Materials and Method
2.1. Reagents
Reagents were obtained from the following commercial sources: high-glucose Dul-
becco’s Modified Eagle Medium (DMEM), William’s E Medium with plating and main-
tenance supplements, penicillin–streptomycin, and LysoTracker™ Red DND-99 (Ther-
mofisher, Carlsbad, CA, USA); LysoSensorTM Yellow/Blue DND-160 (PDMPO) (Ther-
mofisher, Carlsbad, CA, USA); fetal bovine serum (FBS) (R&D Systems, Minneapolis,
MN, USA); human pooled serum (MP Biomedicals, Irvine, CA, USA); Puromycin (Invivo-
gen, San Diego, CA, USA); ExoQuick-TC exosome precipitation solution (SBI, Palo Alto,
CA, USA); primary antibodies- Alix TSG 101, CD9, LAMP1, cathepsin D, β-actin, and cal-
nexin (Santa Cruz, Santa Cruz, CA, USA), HIV p24 (Abcam, Boston, MA, USA); human
pan-exosome isolation kit (Miltenyi Biotec Inc, San Francisco, CA, USA); collagenase (Wor-
thington Biochemical Corporation, Lakewood, NJ, USA); and TBARS (Thiobarbituric acid
reactive substances) assay kit (Cayman Chemicals, Ann Arbor, MI, USA). Bafilomycin A1,
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chloroquine, N-Acetyl-L-cysteine (NAC), and all analytical-grade quality reagents were
from Sigma (St. Louis, MO, USA).
2.2. Cells and Treatments
Primary human hepatocytes (PHH) were obtained from the liver tissue distribution
system (Minneapolis, MN; Pittsburgh, PA; NIH Contract #HSN276201200017C) and main-
tained in serum-free William’s E Medium with maintenance supplement. Hepatocytes
were plated on polyelectrolyte multilayer (PEM) film coating on top of the polydimethyl-
siloxane surface (two-dimensional (2D) culture) to support a long-term cell functionality
since cells plated on collagen undergo fast de-differentiation and lose expression of ethanol
metabolizing enzymes, cytochrome P4502E1 (CYP2E1), and alcohol dehydrogenase (ADH)
in 24 h [14,15]. Thereby, PHH was exposed to 50 mM EtOH treatment for 24 h, followed by
HIV infection, as published earlier [5]. Due to uncertainty in human hepatocytes’ availabil-
ity, we also used human Huh7.5CYP2E1 (RLW) cells [5]. RLW cell line metabolizes ethanol
by CYP2E1 (catalyzing reactive oxygen species (ROS) formation), but do not express ADH,
the primary source of acetaldehyde, Ach. These cells were also transduced with XPack
CMV-XP-GFP-EF1α-Puro expression lentivector, following the manufacturer’s instruc-
tion (XPAK530PA-1, System Biosciences, Palo Alto, CA, USA), to produce GFP-labeled
EVs [16]. Transduced cells were cultured in DMEM medium containing puromycin 1.0
µg/mL for the selection of puromycin-resistance cells, to make a stable cell line and to
minimize the GFP artifact. Furthermore, GFP-positive cells (RLWXP-GFP) were purified
by using fluorescence-activated cell sorting and imaged on fluorescence microscopy (Sup-
plementary Materials Figure S1a). RLWXP-GFP cells expressing GFP were comparable to
parent RLW cells in viability and growth kinetics (Supplementary Materials Figure S1b,c).
Because these cells do not produce Ach, we exposed them to the acetaldehyde-generating
system (AGS). AGS contains yeast ADH as a source of enzyme, nicotinamide adenine
dinucleotide as a co-factor, and 50 mM EtOH (substrate for ADH), and it continuously
produces physiologically relevant amounts of Ach without toxic effects. AGS treatment in
ADH-non-expressing RLW cells recapitulates the effects of ethanol on ethanol-metabolizing
hepatocytes. The transduced RLWXP-GFP cells were exposed to AGS, while PHH were
exposed to 50 mM EtOH and infected with HIVADA at the multiplicity of infection (MOI)
0.1 for 24 h [17]. After overnight HIV-infection, cells were washed with phosphate-buffered
saline (PBS) four times to remove the free virus and incubated in a serum-free medium
for an additional 24 h, and for 72 h to induce death and establish correlation with EVs re-
lease. For lysosome inhibition and alkalization, RLWXP-GFP cells were treated with varying
concentrations of bafilomycin A1 for four hours and chloroquine for overnight. In some
experiments, cells were treated with 5 mM N-acetyl cysteine (NAC) antioxidant (dissolved
in ddH2O, pH 7.4) applied 1 h before AGS treatment. Lysosomes were stained by incu-
bating cells with 50 nM LysoTracker red DND-99 followed by mounting of coverslips
with ProLong™ Gold Antifade mountant with DAPI. The images were acquired on a
Confocal LSM710 microscope and quantified by using Fiji [18]. The pH of acidic organelles,
such as lysosome in RLWXP-GFP cells, was assessed by using LysoSensor™ Yellow/Blue
DND-160 (Thermofisher, Carlsbad, CA, USA), that produces blue fluorescence in neutral
environments and used as per manufacturer’s instructions. Briefly, live cells were incu-
bated with 1 µM LysoSensor Yellow/Blue DND-160 in the pre-warmed medium for 5 min
at 37 ◦C. After washing with a probe-free medium, the samples were viewed with an EVOS
fluorescence microscope (Thermofisher, Carlsbad, CA, USA).
2.3. Experimental Manipulations on FRG-KO Mice with Liver Humanization
Fumarylacetoacetate hydrolase (Fah)-/-, Rag2-/-, common cytokine receptor gamma
chain knockout (FRG-KO; C57BL/6 strain background) male mice transplanted with hu-
man hepatocytes from a single donor (>80% humanization) were purchased from Yecuris
Corporation (Tualatin, OR, USA) and housed in the pathogen-free animal facility at the
University of Nebraska Medical Center (UNMC). Animal studies were carried out accord-
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ing to the guidelines for the humane care of laboratory animals as approved by the UNMC
Animal Care and Use Committee (IACUC 19-034-05FC). Human-specific albumin levels
were assessed in the serum of humanized mice with an ELISA kit (Bethyl Laboratories Inc.,
Montgomery, TX, USA), as described previously [19]. These mice showed average human
albumin levels of 7161 ± 276 µg/mL. The mice were randomized into four groups and
were pair-fed with isocaloric control or 5% EtOH diets, using the NIH-Gao model [20] com-
bined or not with HIV infection. Each group, namely control, HIV, EtOH, and EtOH–HIV,
contained three mice. For intraperitoneal injections, HIV-1ADA was injected at a dose of
105 TCID50/mouse every third day (a total of three injections during the feeding period).
Control uninfected mice received sham-injection with saline. After two days of the last HIV
injection, blood was drawn, and mice were euthanized to harvest livers. Non-humanized
mice served as a negative control for liver humanization.
2.4. OptiPrep Method for EVs Separation from In Vitro Cultures
All EV isolation and characterization procedures corresponded to minimal information
for studies of extracellular vesicles 2018 (MISEV2018) guidelines [21]. A post-treatment
serum-free conditioned medium was collected from an equal number of plated cells,
centrifuged at low-speed (300× g) for 10 min, to remove cells, and then at 2000× g for
10 min at 4 ◦C, to eliminate dead cells and debris. Supernatants were then filtered through
0.22 µm filters and centrifuged at 10,000× g for 30 min to exclude large vesicles and further
ultra-centrifuged at 100,000× g for 70 min at 4 ◦C, using SW28 Ti (k-factor: 245) or SW40Ti
(K factor: 137) rotors (Beckman, Palatine, IL USA) to concentrate small EVs. In some
cases, where the supernatant’s volume was less than 7 mL, EVs were isolated by using
ExoQuick-TC precipitation solution, per manufacturer instructions. To further separate
EVs that contain HIV, EV pellets were further resuspended in 1 mL of 1x PBS, and top-
loaded on PBS diluted 6–18% iodixanol (OptiPrep; Cosmo Bio, Carlsbad, CA, USA) with an
increment of 1.2% as described previously [22]. Gradient fractions were collected from the
top of the gradient in 1 mL increments and transferred to sterile 1.5 mL centrifuge tubes.
Gradients were ultracentrifuge at 100,000× g, using SW41 Ti rotor for 18 h at 4 ◦C, and then
12 fractions containing 1 mL were taken from the top of the gradient (named F1–F12),
diluted in PBS, and pelleted again for one hour at 100,000× g in an SW41 Ti rotor to get
rid of iodixanol from the samples. These fractions were characterized to demonstrate EVs’
presence with markers: transmembrane or GPI-anchored proteins CD9; cytosolic proteins
recovered in EVs, Alix and TSG101; and small EVs (sEVs; size < 200 nm) negative marker
calnexin. Cell lysate from uninfected RLWXP-GFP cells was used as a negative control
to viral protein p24. Alternatively, HIV-free OptiPrep fractions F2–F8 were pooled and
resuspended in sterile 1 x PBS, followed by ultracentrifugation for 70 min at 100,000× g,
using SW41 Ti rotor to pellet EVs for further experiments.
2.5. Isolation of EVs from Liver
EVs were isolated by using differential centrifugation, ultracentrifugation, precipi-
tation methods and purified as described previously with slight modifications [23]. Har-
vested livers from each mouse group were weighed, and an equal amount was used for
isolation of EVs. Livers were homogenized in 10 mL of activating solution consisting of
PBS with 1% collagenase enzyme and incubated at 37 ◦C for ~30 min on gentleMACS
Octo Dissociator with heaters (Miltenyi Biotec, San Francisco, CA, USA), using inbuilt
37C_m_LIDK_1 program. Following homogenization, the suspension was filtered through
40 µm filters, centrifuged at 300× g for 10 min, and then at 2000× g for 10 min at 4 ◦C,
to eliminate tissue fragments, cells, dead cells, and debris, respectively. Supernatants
were then filtered through 1 µm filters and further centrifuged at 10,000× g for 30 min,
to discard unwanted large vesicles. The supernatant was then filtered through 0.45 µm
filters, followed by 0.22 µm filters, and ultracentrifuge at 100,000× g for 70 min at 4 ◦C,
using the SW28 Ti rotor, to concentrate EVs. As these vesicles contained EVs of mouse
and human origin, we utilized a commercial human-specific pan-exosome isolation kit
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(Miltenyi Biotec, San Francisco, CA, USA; Cat 130-110-912), as per manufacturer’s guide-
lines. The kit was based on the immunomagnetic separation of EVs markers, CD9, CD63,
and CD81 expressed on human-specific EVs. EVs obtained from ultracentrifuge step were
further separated from mouse liver derived EVs, utilizing Exosome Isolation Kit Pan,
human (Miltenyi Biotec, San Francisco, CA, USA; Cat 130-110-912), as per manufacturer’s
guidelines. Briefly, EVs resuspended in 1 mL of PBS were incubated with magnetic mi-
crobeads that recognizes the tetraspanin proteins CD9, CD63, and CD81of human origin
and further passed through a µ column in the magnetic field of a µMACS™ Separator.
The magnetically labeled human-EVs are retained within the column, while the unlabeled
mouse run through the column. Besides, to confirm human specificity, we used livers from
non-humanized mice as negative controls. This strategy is summarized in Supplementary
Materials Figure S2a.
2.6. Isolation of EVs from Serum
Serum collection and EV isolation from blood were done according to guidelines and
methodology published previously [21,23,24]. Briefly, blood was collected in serum tubes
(BD Vacutainer, Franklin Lakes, NJ, USA) from treated and untreated humanized mice and
non-humanized mice (negative control). Commercial human pooled serum was used as a
positive control for human-specific antibodies in the immunomagnetic separation method.
Blood was centrifuged at room temperature at 2500× g for 15 min, to collect serum and
subsequently underwent another centrifugation step at 2500× g for 15 min in a clean plastic
tube. We used an equal volume (~400 µL) of serum, to isolate EVs by ultracentrifugation.
The separation of human-specific EVs from mouse origin EVs was achieved by utilizing
a commercial human pan-exosome isolation kit (Miltenyi Biotec Inc, San Francisco, CA,
USA), as described in Section 2.5. The strategy is summarized in Supplementary Materials
Figure S2b.
2.7. Nanoparticle Tracking Analysis (NTA)
EVs isolated from PHH were subjected to NTA, using a NanoSight NS300 (Malvern
Instruments Ltd.; Malvern, UK) with a 405 nm and 60 mV laser source as previously
described [25]. Typically, 1 mL of a diluted EVs preparation was used for the laser light
scattering study. The instrument was set to record at least three recordings per sample
at 23 ◦C for 60 seconds each; NTA software was then used to determine the EVs’ size
distribution. For immunomagnetic separation of EVs, EVs were probed with human EVs
specific cocktails and passed through the magnetic column, to get EVs conjugated with
beads. As the instrument is sensitive to measure any added particles, we separated beads
from EVs by disrupting antigen–antibody interaction utilizing low pH (pH 2.8) 0.1 M
glycine-HCl and passed them through the new magnetic column. EVs were eluted out
with the plunger and the beads retained in the magnetic field of the column. Eluted sEVs
were used for counting. The equivalent volume of immunomagnetic beads without EVs
incubation served as a positive control for bead retention in the column and negative
control for elution of sEVs in eluted buffer. EVs from non-humanized mice and human
serum were used as negative and positive controls for showing the specificity of antibodies
cocktail to human origin.
2.8. ZetaView Tracking Analysis
NTA was performed by using ZetaView Nanoparticle Tracking Analyzer (Particle
Metrix, Inning am Ammersee, Germany) and its corresponding software (ZetaView 8.04.02
SP1), to analyze EVs isolated from RLWXP-GFP samples, as published previously [23].
2.9. Atomic Force Microscopy (AFM)
AFM imaging of the EVs was performed with the use of instruments at the Nanoimag-
ing core facility at the University of Nebraska Medical Center. Samples were processed to
AFM, as described previously with some modifications [23,26]. Briefly, concentrated EVs
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from RLWXP-GFP cells were diluted in PBS buffer, and 10 µL were deposited onto the piece
of freshly cleaved mica. After 2 min incubation, samples were rinsed briefly with several
deionized water drops and dried with a gentle flow of argon. Images were collected with
the MultiMode Nanoscope IV system (Bruker Instruments, Santa Barbara, CA, USA) in
tapping mode at ambient conditions. Silicon probes RTESPA-300 (Bruker Nano Inc., Goleta,
CA, USA) with a resonance frequency of ~300 kHz and a spring constant of ~40 N/m were
used for imaging at scanning rate for about 2.0 Hz. Images were processed by using the
FemtoScan software package (Advanced Technologies Center, Moscow, Russia).
2.10. Transmission Electron Microscopy (TEM)
EVs derived from AGS–HIV-treated RLW cells were isolated as described above,
and the sample was submitted to the University of Nebraska Medical Center Electron
Microscopy Core Facility, to undergo microscopy by a FEI Tecnai G2 Spirit transmission
electron microscope.
2.11. Western Blot Analysis
EVs derived from each fraction (F1–F12) of cells were lysed in RIPA lysis buffer
and processed for immunoblotting as described previously [23]. Total protein was elec-
trophoresed in 4–15% precast protein gels (Bio-Rad, Los Angeles, CA, USA) under reducing
conditions followed by transfer to PVDF membranes. Blots were probed with primary
antibodies associated with sEVs markers—Alix, TSG10, CD9; non-sEV marker—calnexin;
HIV protein—p24 and lysosome marker—LAMP1; and cathepsin D (CTSD) and endoge-
nous control—β-actin. The secondary antibodies were IR dye fluorochrome to anti-mouse
or anti-rabbit (LI-COR, Lincoln, NE, USA) or anti-mouse/anti-rabbit HRP. Images were ac-
quired on Odyssey Imaging System (LI-COR, Lincoln, NE, USA) or on ChemiDoc (Bio-Rad,
Los Angeles, CA, USA).
2.12. Transcriptome Analysis
Total RNA from treated and untreated PHH was isolated as described previously [5].
mRNA sequencing was performed on Illumina next-generation platform. Gene expression
was measured in fragments per kilobase of transcript per million mapped reads (FPKM).
An FPKM cutoff of >1 and p < 0.05 was applied and was used to assess differential gene
expression. Cluster Analysis of differential expression genes was used to estimate the
expression pattern of differential expression genes under different experimental conditions
and clustering of log10(FPKM + 1) values was performed by using Heatmapper (http:
//www.heatmapper.ca) [27]. Upstream transcriptional regulators were identified in the
Ingenuity Pathway Analysis software (IPA, Qiagen, Carol Stream, IL USA), using core
analysis of upregulated and downregulated expressed genes. Top 5 upstream transcription
regulators (p < 0.01) were filtered based on the most significant p-value of overlap with
the dataset differentially expressed genes. To show an association of upstream regulators
with oxidative stress, lysosome and EVs biogenesis, IPA upstream regulator analysis and
functional network analysis was used.
2.13. Activities of Cathepsins
Cathepsin B and L activities were assayed fluorometrically, as described previously [5,28].
2.14. Statistical Analyses
Data from at least three independent experiments were expressed as mean values ± standard
error. Comparisons among multiple groups were performed by one-way analysis of variance
(ANOVA), using a Tukey post hoc test. For comparisons between two groups, we used
Student’s t-test. A probability value of 0.05 or less was considered significant.
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3. Results
3.1. Ethanol Stimulates EV Release from HIV-Infected Hepatocytes
PLWH are more likely to abuse alcohol [29]. Studies from the past few years have
implicated aberrant biogenesis of EVs in the pathogenesis of various alcoholic liver dis-
eases and people with chronic HIV infection [6,30]. Given that hepatocytes represent the
majority of cells in the liver and are the primary site of ethanol metabolism, we sought
to investigate the effects of alcohol and HIV on EVs release from hepatocytes. PHH and
RLWXP-GFP cells were pre-exposed to EtOH and AGS, respectively, followed by HIV in-
fection, as described in Materials and Methods. Alcohol exposure in hepatocytes has
been shown to increase HIV expression previously [5]. Conditioned medium was used to
separate and concentrate EVs with the OptiPrep method, as shown in the schematic Figure
1a. Isolated EVs demonstrated heterogeneous topography of EVs as assessed by AFM
under the tapping mode by immobilizing vesicles on positively charged APS-mica surface
(Figure 1b). TEM analysis revealed a heterogeneous population within the expected size
range of sEVs (<200 nm) with spherical morphology (Figure 1c). Purification of EVs from
HIV is required due to a similar size range and could be obtained by OptiPrep density
gradient. Immunoblotting of EV fractions collected from density gradient preparation
demonstrated the enrichment for EVs proteins, Alix (F3–F11), TSG 101 (F2–F8), CD9 (F2–
F10), and was negative for endoplasmic reticulum protein, calnexin. HIV-specific protein
P24 was enriched in fractions F9–F12 in OptiPrep fractions (14.4–18%) and was excluded
from EVs analysis (Figure 1d). Size distribution assessed by ZetaView and NanoSight
revealed that more than 90% of particles were distributed in the range of typical sEVs (size
< 200 nm). Here, EVs showed peak values ranged from mean ± SE: 87.2 ± 30 nm (control),
86.2 ± 35.6 nm (EtOH), 95.3 ± 37.1 nm (HIV) and 102.9 ± 38.5 nm (EtOH–HIV) groups in
PHH; and 122.1± 63.8 nm (control), 122.5 ± 70.8 nm (AGS), 109.9 ± 58.1 nm (HIV) and
106.2 ± 46.4 nm (AGS–HIV) groups in RLWXP-GFP cells (Figure 1e). Combined treatment
of EtOH and HIV in PHH and AGS and HIV in RLWXP-GFP cells significantly increased
the EVs concentration, as compared to their respective controls (Figure 1f). Moreover,
endogenous quantitation of GFP-labeled endosomal EVs in the RLWXP-GFP cells revealed
an increase in the AGS–HIV group, as compared to the respective controls (Figure 1f).
Quantification of GFP-expressing EVs in RLWXP-GFP from five to nine randomly captured
images was performed by using Fiji and expressed as average absolute counts.
3.2. Hepatocyte-Derived EVs Are Enriched in the Serum of Ethanol-Fed and HIV-Infected
Humanized Mice
Based on the premise that EVs biogenesis is altered in alcoholic liver disease and
PLWH, we studied whether exposure to EtOH and HIV affects EVs release in humanized
FRG-KO mice. FRG-KO mice were either fed EtOH or control diet and infected with HIV-1,
as mentioned in Materials and Methods. The specificity of the human pan-exosome isola-
tion kit for EVs of human origin was confirmed by using EVs from non-humanized mice
and human serum as negative and positive controls, respectively. Here, human-specific
EVs were detected only in humanized mice transplanted with human hepatocytes. Size dis-
tribution assessed by NanoSight revealed that more than 75% of EVs were distributed in
the range of typical sEVs size of <200 nm (Figure 2a). The results from NanoSight in EtOH–
HIV group of mice revealed no statistical difference in the number of total hepatocyte-
specific EVs with mean value 8.786e + 007 EVs/mL (range 3.980e + 007–1.610e + 008) vs.
EtOH mean value 7.486e + 007 EVs/mL (range 6.090e + 007–9.330e + 007); and HIV mean
value 1.384e + 008 EVs/mL (range 8.430e + 007–2.100e + 008) (Figure 2b). EtOH–HIV
group-derived EVs in the size range of sEVs (<200 nm) and mean value of 5.569e + 007 EVs/mL
(range 1.860e + 007–1.210e + 008) was also comparable to that of EtOH mean value 5.604e + 007 EVs/mL
(range 3.970e + 007–7.000e + 007) and HIV mean value 9.702e + 007 EVs/mL (range 5.100e + 007–
1.520e + 008) (Figure 2c). Since the EVs derived from humanized mice also include EVs
from mouse hepatocytes (~20% of the liver after humanization), our method based on
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immunomagnetic separation for human-specific EVs was optimal to characterize the
treatment-induced changes.




Figure 1. Ethanol (EtOH) stimulates EV release from HIV-infected hepatocytes. (a) Schematic demonstration of the process 
of extracellular vesicles (EVs) separation and OptiPrep density gradient method. (b) Topographic profiling of EVs, using 
atomic force microscopy (AFM) reveals a heterogeneous population of spherical particles of RLWXP-GFP cells. (c) Transmis-
sion electron microscopy of EVs derived from acetaldehyde-generating system (AGS)–HIV-infected RLW cells reveals a 
heterogeneous population of small EVs (<200 nm). Magnification 110,000 x and scale bar 100 nm. (d) Representative im-
munoblotting images from AGS–HIV treated group show protein expression from F1-F12 fraction of EVs and RLWXP-GFP 
cells lysate for EV-associated proteins ALIX, TSG101, and CD9, small extracellular vesicle (sEV) negative marker calnexin, 
and HIV protein p24 enrichment in fractions F9-F12. (e) The size distribution of pooled EVs from F2–F8 fractions, released 
from primary human hepatocytes (PHH) EVs and RLWXP-GFP-EV by NanoSight and ZetaView, respectively. (f) Dot plots 
show the concentration of EVs released from EtOH treated HIV-infected PHH and acetaldehyde-generating system (AGS)-
treated HIV-infected RLWXP-GFP cells EV by NanoSight and ZetaView, respectively. (g) AGS–HIV treatment in RLWXP-GFP 
cells induces more endogenous EVs, as compared to their respective controls. The bar graph shows quantification of EVs 
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croscope at 10x magnification. Results represent the mean ± SEM. (e–g) Statistical significance between groups is indicated 
by asterisk(s) and determined by one-way ANOVA (*** p ≤ 0.001 and ** p ≤ 0.01). 
Figure 1. Ethanol (EtOH) stimulates EV release from HIV-infected hepatocytes. (a) Schematic demonstration of the
process of extracellular vesicles (EVs) separation a d OptiPrep density gradient method. (b) Topographic profiling
of EVs, using atomic force microscopy (AFM) reveals a heterogeneous population of spherical particles of RLWXP-GFP
cells. (c) Transmission electron microscopy of EVs derived from acetaldehyde-generating system (AGS)–HIV-infected
RLW cells reveals a heterogeneous p pulation of small EVs (<200 nm). Magnification 110,000× and scale bar 100 nm.
(d) Representative immunoblotting images from AGS–HIV treated group show protein expression from F1–F12 fraction
of EVs and RLWXP-GFP cells lysate for EV-associated proteins ALIX, TSG101, and CD9, small extracellular vesicle (sEV)
negative marker calnexin, and HIV protein p24 enrichment in fractions F9–F12. (e) The size distribution of pooled EVs from
F2–F8 fractions, released from primary human hepatocytes (PHH) EVs and RLWXP-GFP-EV by NanoSight and ZetaView,
respectively. (f) Dot plots show the concent ation of EVs released from EtOH treated HIV-inf cted PHH and acetaldehyde-
generating system (AGS)-treated HIV-infected RLWXP-GFP cells EV by NanoSight and ZetaView, respectively. (g) AGS–HIV
treatment in RLWXP-GFP cells induces more endogenous EVs, as compared to their respective controls. The bar graph shows
quantification of EVs with Fiji software by counting GFP expressing EVs from five to nine randomly captured images with a
fluorescence microscope at 10× magnification. Results represent the mean ± SEM. (e–g) Statistical significance between
groups is indicated by asterisk(s) and determined by one-way ANOVA (*** p ≤ 0.001 and ** p ≤ 0.01).
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and EtOH–HIV, and non-humanized mice. (b) Graph showing the concentration of total human hepatocyte specific EVs 
obtained from the livers. (c) Graph showing the concentration of EVs in the size range of sEVs (<200 nm) obtained from 
the livers. (d) The size distribution of human hepatocyte specific EVs in the serum. (e) Total human hepatocyte specific 
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the concentration of EVs in one capture in NanoSight. Equal amounts of livers and serum from untreated and treated mice 
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Figure 2. Hepatocyte-derived EVs in the liver and serum from liver-humanized and non-humanized mice. (a) The size
distribution of hepatocyte-specific EVs for the size range 0.5–500.5 nm in the liver from humanized control, EtOH, HIV-1
and EtOH–HIV, and non-humanized mice. (b) Graph showing the co centratio of total huma hepatocyte specific EVs
obtained from the livers. (c) Graph showing the concentration of EVs in the size range of sEVs (<200 nm) obtained from the
livers. (d) The size distribution of human hepatocyte specific EVs in the serum. (e) Total human hepatocyte specific EVs in
the serum. (f) The serum concentration of human hepatocyte EVs in the size range of sEVs. The single dot represents the
concentration of EVs in one capture in NanoSight. Equal amounts of livers and serum from untreated and treated mice
were used as the starting material to isolate total EVs. Non humanized mice served as a negative, and human serum as
positive to the human-specific EVs. All conditions and dilutions were kept identical for all the treatment groups. NanoSight
NS300 was used to assess concentration after adjusting for dilutions. Data for the control group were derived from the
single control mouse and two pooled control mice. Non-humanized mice data were derived from pooled samples of three
mice. Statistical significance between treatment groups is indicated by asterisk(s) and determined by one-way ANOVA
(**** p ≤ 0.0001, *** p ≤ 0.001, ** p ≤ 0.01, and * p ≤ 0.05).
Based on the premise that EVs are increased in the serum of patients with alcoholic
liver disease and in PLWH [13,31], we sought to investigate the combined effect of EtOH
and HIV on the release of human hepatocyte-specific EVs to the serum of humanized mice.
Size distribution assessed by NanoSight revealed that more than 85% of particles distributed
in the range of typical sEVs (Figure 2d). The results from NanoSight in EtOH–HIV group of
mice demonstrated statistically significant increase in numbers of total hepatocyte-specific
EVs (mean value of 1.684e + 012 EVs/mL (range 7.910e + 011–2.620e + 012)) compared
with EtOH group (3.091e + 011 EVs/mL (range 6.730e + 010–6.870e + 011)) and HIV group
of mice (1.350e + 012 EVs/mL (9.470e + 011–1.890e + 012)) (Figure 2e). Similarly, human
hepatocyte-derived EVs of sEVs size range were significantly higher in the serum of EtOH–
HIV group (mean value of 6.795e + 011 EVs/mL (range 1.930e + 011–1.210e + 012)) vs.
mean value of EtOH (2.568e + 011 EVs/mL (range 6.080e + 010–6.840e + 011)), and HIV
group (4.514e + 011 EVs/mL (1.800e + 011–8.670e + 011)) (Figure 2f).
3.3. Alcohol–HIV Treatment Regulates Genes Associated with Lysosome and EVs Release
in Hepatocytes
We examined the differentially expressed genes in EtOH–HIV treated PHH group,
as compared to EtOH and HIV groups and identified upstream regulators that regulate
genes associated with EVs biogenesis, oxidative stress, and lysosome-related diseases
and functions. Sixty-three (63) differentially expressed genes in the EtOH–HIV group,
including upregulated 50 and downregulated 13 genes, were identified by using DEGseq
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R package, and hierarchical clustering analysis was carried out with the log10 (FPKM + 1)
of union differentially expressed genes of all comparison groups (Figure 3a). IPA up-
stream regulator analysis identified 193 significant upstream regulators (p-value < 0.05)
in the category of ligand-dependent nuclear receptor (1), transcription regulator (109),
kinase (31), and enzyme (52), and out of these categories, five (RORA, ZBTB16, RHOB,
HNF4a, and FKBP5) were upregulated in the EtOH–HIV group. Association of these
upstream regulators with their targets in the dataset is depicted in Figure 3b. Integration
analysis of the upstream regulators with their targets, using toxicity and canonical path-
ways, revealed dysregulated downstream genes that are involved in the accumulation
of oxidative stress (related to genes PIK3R1, FKBP5, CYP3A5, SOD1, CYP2E1, TSG101,
GPX1, and TAT1), dysregulation of lysosomal function (CTSB, IL6, Rab27A, TSG101, Rab
7A, Rab11A, PIK3R1, LAMP1, and Rab5A) and EVs biogenesis as evidenced by regulating
the pathways associated with phagosome formation (PIK3R1, ICAM1) clathrin-mediated
endocytosis signaling (PIK3R1, Rab5A, TSG101, Rab7A, and Rab11A) phagosome matu-
ration (LAMP1, Rab 7A, and Rab11A), and caveolar-mediated endocytosis signaling Rab
5A (Figure 3c).
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[13], we sought to check the effects of lysosome impairment on EVs release. Cathepsins B 
and L constitute the most abundant proteases in lysosomes, and EtOH treatment de-
creases these enzymes’ activities and is suggestive of lysosomal impairment [28]. 
Thus, we visualized the AGS–HIV-induced lysosomal impairment, and bafilomycin 
A1 was added as a positive control for lysosome inhibition. AGS–HIV treatment in the 
RLWXP-GFP cells significantly inhibited cathepsin B and cathepsin L activities, as compared 
to the AGS and HIV groups (Figure 4a). To further elucidate the crosstalk between im-
pairment of lysosome activity and EVs secretory pathways, we performed a series of cell 
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Figure 3. Differentially expressed genes (DEGs) and upstream regulator analysis of primary human hepatocytes and their
interaction wi h target molecules regulating oxidative stres , l some related dise ses and EVs biogen sis. (a) Heat maps
and hierarchical clustering-based dendrograms of DEGs from different experimental groups. Expression variability between
the groups is indicated by the Z score, here shades of red and green color denote down and upregulation of genes,
respectively. (b) An integrated network of RORA, ZBTB16, RHOB, HNF4a, and FKBP5 upstream regulators and their target
genes. All the targets and upstream regulators were differentially regulated in the dataset based on Ingenuity Pathway
Analysis (IPA) upstream regulator analysis. For the color code, refer to the prediction legend. (c) Interaction of RORA,
ZBTB16, RHOB, HNF4a, and FKBP5 with target genes to regulate oxidative stress (cyan), lysosome-related disease, and
functions (magenta) and exosome biogenesis (yellow). Different types of interaction molecules are mentioned in the legend.
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3.4. Alcohol–HIV Treatment in Hepatocytes Causes Oxidative Stress and Downregulates
Expression of LAMP1, Which Is Associated with EVs Release
Given the association of EV-associated genes with oxidative stress and lysosomal
function in our IPA upstream regulator analysis in the dataset, and as shown previously [13],
we sought to check the effects of lysosome impairment on EVs release. Cathepsins B and L
constitute the most abundant proteases in lysosomes, and EtOH treatment decreases these
enzymes’ activities and is suggestive of lysosomal impairment [28].
Thus, we visualized the AGS–HIV-induced lysosomal impairment, and bafilomycin
A1 was added as a positive control for lysosome inhibition. AGS–HIV treatment in the
RLWXP-GFP cells significantly inhibited cathepsin B and cathepsin L activities, as compared
to the AGS and HIV groups (Figure 4a). To further elucidate the crosstalk between im-
pairment of lysosome activity and EVs secretory pathways, we performed a series of cell
stimulation experiments. We treated hepatocytes with various concentrations of the drugs
bafilomycin A1 and chloroquine, to increase the lysosomal pH, and we established differ-
ential levels of cathepsin B and L activities suppression. We observed the concentration-
dependent decrease in enzyme activities at 25 and 50 nM for bafilomycin A1 (Figure 4b),
and at 2.5 and 50 µg/mL for chloroquine (Figure 4c). The dose-dependent decrease in
cathepsin activities was associated with an increase in the sEVs concentration for both drugs,
as assessed with the NTA (Figure 4c,d). Given the crucial role of LAMP1 in the interaction
of MVBs to the lysosome or phagosome maturation [32], we also checked the expression of
LAMP1 protein expression with immunofluorescence and immunoblotting. We observed
a significant decrease in the expression of LAMP1 in the AGS–HIV group, as compared
to other groups by quantifying images acquired on confocal microscopy (Figure 4e) and
in Western blots (Figure 4f). The decrease in cathepsin activities in bafilomycin A1 and
chloroquine treated cells showed a significant dose-dependent increase in EVs release,
as compared to the untreated control, thereby confirming the lysosome’s role impairment
in EVs release. Furthermore, pretreatment with antioxidant NAC in the AGS–HIV group
ameliorated the enhanced sEVs release (Figure 4h) and restored lysosomes numbers as
assessed with LysoTracker red dye (Supplementary Materials Figure S3), suggesting the
role of oxidative stress with the lysosome and in EVs production.
3.5. HIV-1 Inhibits Cathepsin B/L Activity, and Lysosomal Dysfunction in the Ethanol-Fed
Liver-Humanized Mice
In hepatocytes, the decline in cathepsin activities by ethanol metabolism has been
reported before and was linked to oxidative stress induction [5]. Our lab also demonstrated
earlier that EtOH and HIV treatments could induce oxidative stress in the liver in vivo [5].
Similarly, we noticed a significant increase in the activation of oxidative stress in humanized
mice’s liver tissues when assessed with the TBARS assay (Figure 5a). In line with our
findings in vitro, we also observed significant inhibition in the activity of cathepsin B and
cathepsin L in the liver tissue of mice exposed to EtOH and HIV, as compared to HIV
and control groups (Figure 5b,c). Cathepsin D maturation is regulated by the activity of
cathepsin B and L, so we checked the expression of pro–cathepsin D and mature cathepsin
D, produced in the biosynthetic pathway as a precursor pro–cathepsin D (~52 KDa or
intermediate cathepsin D ~48 KDa) and sorted to the endolysosomal compartment, where it
is processed into a mature form (~34 and 14 KDa) at acidic pH. EtOH-fed and HIV infected
mice group showed a significant decrease in mature cathepsin D expression, as compared
to control mice (Figure 5d). We observed a significant increase in the EtOH and a trend of an
increase in the expression of pro– and intermediate cathepsin D in other treatment groups,
which showed no significant difference from mice fed with the control diet (Figure 5d).
Besides, LAMP1 expression was significantly downregulated in EtOH-fed HIV-infected
mice (Figure 5e).
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Figure 4. AGS–HIV treatment inhibits lysosomal activities and downregulates LAMP1 in RLWXP-GFP cells. (a) Cathepsin B 
and cathepsin L activities were significantly suppressed by AGS treatment in HIV-infected RLWXP-GFP cells. Bafilomycin 
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Figure 4. AGS–HIV treatment inhibits lysosomal activities and downregulates LAMP1 in RLWXP-GFP cells. (a) Cathepsin B
and cathepsin L activities were significantly suppressed by AGS treatment in HIV-infected RLWXP-GFP cells. Bafilomycin
A1 was selected o inhibi ath psin activities and served as a positiv c ntrol for lysosome inhibition. (b) Bafilomycin A1
was used, at different concentrations, to derive gradient in the activities of cathepsins B and L. (c) Chloroquine was used at
low (2.5 µg/mL) and high concentration (50 µg/mL), to derive gradient in the activities of cathepsin B and cathepsin L.
(d,e) EVs count in the size range of sEVs (50–200 nm) with different concentrations of bafilomycin A1 (d) and chloroquine
(e), as assessed with NTA. (f) RLWXP-GFP cells grown on the coverslip and treated with AGS and HIV were probed with
LAMP1 antibody, and images were acquired on confocal microscopy. DAPI was used to counterstain the nucleus. For the
quantification, Lamp1 intensity was measured from at least three independent images per group and divided by the total
number of DAPI positive nuclei. Images were acquired on a 40x objective and scale bar = 50 µm. (g) Total protein from
whole-cell lysates was extracted from untreated and treated groups and analyzed for lysosome-associated membrane
protein (LAMP1) by Western blot. β-actin was used as a loading control. Representative Western blot and densitometric
analysis of the LAMP1 level are shown. (h) EVs count in the size range of sEVs (50–200 nm) from the cells pretreated with or
without the addition of N-Acetyl-L-cysteine (NAC). (a–h) Data were obtained from at least three independent experiments
and presented as Mean ± SEM. Statistical significance between treatment groups is indicated by asterisk(s) and determined
by one-way ANOVA (*** p ≤ 0.001, ** p ≤ 0.01, and * p ≤ 0.05).
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4. Discussion 
EVs number and contents are often altered in response to various stresses or patho-
logical stimuli [23,33]. For instance, alcohol has been shown to stimulate EVs release from 
hepatocytes, microglia, and other cell types [33,34]. HIV induces EVs secretion from vari-
ous cell types, including (but not limited to) macrophages and neurons [23,35]. Studies 
from our laboratory also demonstrated that ethanol metabolite, acetaldehyde combined 
with HIV infection, induced apoptotic bodies from the HIV- and ethanol-exposed hepato-
cytes, thereby providing detrimental consequences for activation of non-parenchymal 
cells [5]. However, the release of small EVs from hepatocytes has not been investigated in 
the settings of HIV and ethanol/ethanol metabolites in the liver cells. Hepatocytes, the 
primary site of ethanol metabolism, comprise about 80% of liver cells, and cross-talking 
with non-parenchymal cells can program liver inflammation and fibrosis. In this way, 
they contribute to the rapid development of end-stage liver disease in alcohol-abusing 
Figure 5. EtOH feeding causes oxidative stress and inhibits the activity of cathepsin B/L and the expression of cathepsin D in
the liver of HIV-exposed liver-humanized mice. (a) Thiobarbituric acid reactive substances (TBARS) assay. (b,c) Cathepsin
B (b) and cathepsin L (c) activities significantly suppressed by EtOH feeding in the liver of HIV-infected humanized
mice. (d) Representative Western blot and densitometric analysis of mature cathepsin D (33 and 14 KDa) and pro–and
intermediate cathepsin D (52 and 48 KDa, respectiv ly). (e) Representative Western blot and densitometric analysis of
LAMP1. (d,e) β-actin was used as a loading control. Statistical significance between treatment groups is indicated by
asterisk and determined by two tailed Student’s t-test (* p ≤ 0.05).
4. Discussion
EVs number nd contents are often al ered in response to various stresses or patho-
logical stimuli [23,33]. For instance, alcohol has been shown to stimulate EVs release
from hepatocytes, microglia, and other cell types [33,34]. HIV induces EVs secretion from
various cell types, including (but not limited to) macrophages and neurons [23,35]. Stud-
ies from our laboratory also demonstrated that e hanol metabolite, a etaldehyde combined
with HIV infectio , indu d apo totic bodies fro the HIV- and ethanol-exposed hepa-
tocytes, thereby providing detrimental consequences for activation of non-parenchymal
cells [5]. However, the release of small EVs from hepatocytes has not been investigated
in the settings of HIV and ethanol/ethanol metabolites in the liver cells. Hepatocytes,
the primary site of ethanol metabolism, comprise about 80% of liver cells, and cross-talking
with non-parenchymal cells can program liver inflammation and fibrosis. In this way,
they contribute to the rapid development of end-stage liver disease in alcohol-abusing
PLWH. Thus, here, we investigated whether HIV and ethanol/ethanol metabolites modu-
late EVs release from hepatocytes and, in this regard, which mechanisms are involved in
regulating EVs secretion.
In our study, both PHH exposed to ethanol, and RLWXP-GFP cells treated with AGS [36],
showed the enhanced EVs release from HIV-infected cells, as compared to cells treated with
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either alcohol or HIV. Further, no difference in the ratio of EVs to protein concentration
demonstrated the purity of EVs (Supplementary Materials Figure S4), suggesting that the
increase in the number secreted from the equal number of cells in AGS–HIV treatment
group is due to an increase in the EVs/cell, as we consistently observed an increase in EVs’
numbers, as compared to other groups. We have previously shown that hepatocytes could
be infected with HIV in vitro and in vivo [5,19]. Most of the EVs (>90%) were sEVs in size
range of 50–200 nm. Since the size of sEVs is similar to HIV, it is imperative to separate sEVs
from HIV [22,37], which we accomplished by using the OptiPrep fractionation method.
EVs are released to maintain homeostasis, which compensates for the exposure to the
stress stimuli that cells can manage without affecting their viability [38]. Hence, when the in-
clusion of a pan-caspase inhibitor prevented apoptosis in hepatocytes treated with HIV and
EtOH and further incubated for an additional three days, we observed the intensive sEVs
release. In contrast, hepatocytes exposure to HIV and EtOH in the absence of pan-caspase
inhibitor reduced sEVs secretion under the same treatment conditions, suggesting the
preferential role of sublethal damage in EVs release (Supplementary Materials Figure S5).
Since sEVs number is declined when cells undergo apoptosis and based on our previous
results, we observed apoptosis in AGS-pretreated cells in 48–72 h post-HIV exposure [5].
Here, we have chosen a shorter infection duration for EVs studies limited to one day of
HIV infection after AGS pretreatment. These conditions were suboptimal for apoptosis but
ensured more EVs release.
The EVs release is regulated by lysosome activity in hepatocytes as suppression of en-
zyme activity with bafilomycin A1 and chloroquine intensifies EVs secretion. Both bafilomycin
A1 and chloroquine are shown to impair lysosome activity by lowering the acidic pH (more
alkaline) [39,40]. Similarly, AGS–HIV treatment in RLWXP-GFP cells neutralized the lysoso-
mal acidic pH (Supplementary Materials Figure S6) and showed inhibition in lysosomal
activities. Thus, the reduction in cathepsin B and L activities is likely associated with
decreased lysosome expression (visualized by decreased LAMP1 content) and neutralizing
of lysosomal acidic pH. This finding was not surprising since ethanol is known to impair
lysosome activity [5], and ethanol-induced EVs secretion from liver cells has already been
demonstrated [9,41]. The association of lysosome activity impairment and EVs release was
demonstrated in other tissues [41,42]. This study discovered that ethanol-metabolism and
HIV-induced suppression of lysosomal activity in hepatocytes increases EVs release from
these cells.
In our in vitro model, HIV and ethanol metabolism enhances EVs release under
oxidative stress conditions, which are sufficient to induce a level of lysosome damage
that does not kill the cells. The NGS study results predict that hepatocytes exposed to
HIV and ethanol activated stress-regulated genes and provided lysosome dysfunction
in HIV and ethanol-exposed PHH, which potentially increases EVs release from these
cells. Our in-silico data revealed that PHH exposed to EtOH–HIV upregulated upstream
regulators who regulate genes associated with oxidative stress, lysosomal diseases, and EVs
secretion. In our experiments, pretreatment with antioxidant NAC of EtOH–HIV exposed
cells restored the lysosomes and suppressed the EVs release, supporting the regulation of
EVs release and lysosome by oxidative stress.
To confirm these in vitro findings by in vivo experiments and study in vivo effects of
alcohol and HIV on human hepatocyte-derived EVs, we utilized the FRG-KO humanized-
liver mouse model [43]. Mice with humanized livers have been used previously for
alcohol studies [5,44]. The advantage of this model is that FRG-KO mice livers show
robust engraftment of human hepatocytes. Hepatocytes cannot be infected with HIV
productively, and HIV infection is abortive [5]. Our previous study also demonstrated
that in the absence of immune system, the infection persists for 2 days [19]. Therefore,
in the current study, we injected mice with HIVADA injections every third day. FRG-KO
mice in our study showed HIV viral load varying from 394–1486 copies/mL for the HIV
group and 350–404 copies/mL in alcohol-fed HIV-infected mice. While EVs in the serum
of alcohol-abusing PLWH could come from various organs and subpopulation of cells,
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and only a part of them is released from hepatocytes, our chimeric liver humanized mice
overcome this limitation since the only human cells these mice possess are engrafted
human hepatocytes. Thus, the EVs of human origin are hepatocyte-specific. In our study,
EVs from serum and livers of humanized mice were separated based on the human-specific
pan-exosome markers (a kit from Miltenyi Biotec Inc, San Francisco, CA, USA) as described
in Results. Subsequently, we detected the highest level of human EVs in the serum of
ethanol-fed and HIV-infected mice, confirming our in vitro findings. Here, we found no
difference in HIV–alcohol-induced cell death, which is evident from similar ALT levels
in all groups (Supplementary Materials Figure S7). Besides, HIV and alcohol did not
cause significant depletion of human hepatocytes as judged by human albumin levels
(not shown), but induced oxidative stress in hepatocytes, as evidenced by increased lipid
peroxidation (TBARS assay) in the liver tissues.
We observed a significant increase in the hepatocyte-derived EVs from the serum of
mice from the EtOH–HIV group. In accordance to our in vitro findings, in HIV-exposed
ethanol-fed mice, there was a reduction in lysosome membrane protein, suppression of
cathepsins B and L activities, and inhibition of cathepsin D enzyme maturation in liver
tissue, indicating lysosome impairment in mice with the highest levels of hepatocyte-
derived human EVs in the serum. The reduction in cathepsin D activity has been shown to
cause a significant decline in lysosomal functions [45]. Cathepsin D enzyme is synthesized
as an inactive precursor, subsequently processed by cathepsin B and L [46]. Inhibition of
cathepsin B and L activities with their specific inhibitors induced accumulation of 48 KDa
intermediate cathepsin D by slowing down the cleavage of later into mature two-chain
enzyme consisting of a light 14 KDa amino-terminal domain and a heavy 34 KDa carboxyl-
terminal domain [46]. Thus, exposure of liver cells to HIV and ethanol metabolites impairs
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bodies (MVBs). MVBs th t c tain many intraluminal vesicles either release EVs by fusion with the
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5. Conclusions
In summary, our data demonstrate that ethanol metabolism and mainly acetaldehyde
causes oxidative stress in HIV-infected hepatocytes. This results in lysosome impairment
associated with decreasing cathepsin activities and downregulation of lysosome protein
markers, which, in turn, potentiates EVs release from the hepatocytes. We believe that
these results contribute to further understanding underlying mechanisms associated with
lysosome impairment and EVs secretion in HIV-induced liver disease progression in
alcohol-abusing PLWH.
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